Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.38%
#2 Victoria VR Victoria VR +11.93%
#3 Movement Movement +11.39%
#4 Palladium Network Palladium Network +9.28%
#5 DMT-NAT DMT-NAT +6.25%
#6 Cryptopia Cryptopia +4.73%
#7 Pons Pons +4.23%
#8 GRVT Token GRVT Token +3.85%
#9 MarsCoin MarsCoin +3.69%
#10 COTI COTI +3.65%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Setări
Limbă
ROMâNă
Monedă
USD
Temă
Novo Nordisk A/S Novo Nordisk A/S

Novo Nordisk A/S

NOVO-B
Rang în acțiuni #88
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the... Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Preț acțiune
$47.55
Ultima sincronizare: 2026-08-12
Capitalizare de piață
$211.25B
Schimbare (1 zi)
-2.51%
Schimbare (1 an)
-6.99%
Țară
DK
Tranzacționează Novo Nordisk A/S (NOVO-B)

Categorie

Healthcare
Raport P/S pentru Novo Nordisk A/S (NOVO-B)
Raport P/S la data de February 2026 TTM: 4.47
Conform celor mai recente rapoarte financiare și prețului acțiunilor Novo Nordisk A/S, raportul P/S actual (TTM) este 4.47. La sfârșitul anului 2026, compania avea un P/S de 0.
Istoricul raportului P/S pentru Novo Nordisk A/S din 2026 până în 2026
Raport P/S la sfârșitul fiecărui an
An Raport P/S Schimbă
Nu sunt suficiente date pentru perioada selectată.
Raport P/S pentru companii similare sau competitoare
Companie Raport P/S Diferență raport P/S Țara
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
14.97 235.27%
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
6.31 41.28%
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
7.06 58.02%
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
4.66 4.33%
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
4.90 9.81%
US